Published June 28, 2022 | Version v1
Journal article Open

Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Authors/Creators

  • 1. Senior Lab Tech, PCLMA, KFMC, Riyadh, Saudi Arabia
  • 2. Lab Tech I, PCLMA, KFMC, Riyadh, Saudi Arabia
  • 3. Medical Technologist II, PCLMA, KFMC, Riyadh, Saudi Arabia

Description

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation.

Keywords: biochemistry; new coronary pneumonia; hematology; SARS-CoV-2.

Title: Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Author: Yasir.A.Ahmed, Ayeed Marfo AlEnizi, Mansour Farhan AlEnizi, Fahad Mohammed AlWallan

International Journal of Healthcare Sciences

ISSN 2348-5728 (Online)

Vol. 10, Issue 1, April 2022 - September 2022

Page No: 90-99

Research Publish Journals

Website: www.researchpublish.com

Published Date: 28-June-2022

DOI: https://doi.org/10.5281/zenodo.6771809

Paper Download Link (Source)

https://www.researchpublish.com/papers/guidelines-on-biochemicalhematological-monitoring-of-covid-19-patients

Notes

International Journal of Healthcare Sciences, ISSN 2348-5728 (Online), Research Publish Journals, Website: www.researchpublish.com

Files

Guidelines on Biochemical-28062022-2.pdf

Files (824.2 kB)

Name Size Download all
md5:881e99439495dda14e24fcbde1732653
824.2 kB Preview Download

Additional details

Related works

Is derived from
Journal article: https://www.researchpublish.com/papers/guidelines-on-biochemicalhematological-monitoring-of-covid-19-patients (URL)
Is published in
Journal article: 2348-5728 (ISSN)

References

  • [1] Singh A, Sood N, Narang V, Goyal A. Morphology of COVID- 19-affected cells in peripheral blood film. BMJ Case Rep 2020;13: e236117.
  • [2] Huang I, Pranata R. Lymphopenia in severe coronavirus disease- 2019 (COVID-19): systematic review and meta-analysis. J. Intensive Care 2020; 8: 36.
  • [3] Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58: 1021–8.
  • [4] Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur J Allergy Clin Immunol 2020; 75: 1730–41.
  • [5] Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta 2020; 509: 180–94.
  • [6] Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol Apr 3 2020. https://doi.org/10.1002/ jmv.25819 [Epub ahead of print].
  • [7] Becker RC. COVID-19 update: covid-19-associated coagulopathy. J Thromb Thrombolysis 2020; 50: 54–67.
  • [8] Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020; 8: 693.
  • [9] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and followup: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 2950–73.
  • [10] Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120: 1004–24.
  • [11] Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBio Med 2020; 58: 10295.
  • [12] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1233–4.
  • [13] Gando S, Fujishima S, Saitoh D, Shiraishi A, Yamakawa K, Kushimoto S, et al. The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome. Thromb Res 2020; 191: 15–21.
  • [14] Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120: 876–7.
  • [15] Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, et al.COVIDand coagulation: bleedingand thrombotic manifestations of SARS-CoV2 infection. Blood 2020; 136: 489–500.

Subjects

Paper Download Link (Source)
https://www.researchpublish.com/papers/guidelines-on-biochemicalhematological-monitoring-of-covid-19-patients